Core Viewpoint - The announcement highlights that the innovative drug Pirlosil (brand name: XuanYueNing®) developed by XuanZhu BioTech, a non-wholly owned subsidiary of the company, has been included in the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List, which will take effect on January 1, 2026 [1] Group 1 - The inclusion of XuanYueNing® in the national insurance list will enhance its affordability and accessibility for patients [1] - This development is expected to promote the market penetration and increase sales scale of the drug [1] - The long-term operational development of XuanZhu BioTech is positively impacted by this insurance negotiation outcome [1] Group 2 - The company will actively cooperate to implement the insurance policy and continue to work on hospital access [1] - There is a focus on expanding coverage in core and broader market areas to improve patient access to medication [1]
四环医药(00460)：创新药轩悦宁®首次纳入国家基本医保药品目录